C4 Therapeutics (CCCC) EBIT Growth (3y) (2022 - 2026)
C4 Therapeutics (CCCC) EBIT Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 89.72% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 44.54% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -26.00% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -18.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 44.34% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 81.27% |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | 11.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.07% |
| Mar 31, 2026 | 8.46% |
| Dec 31, 2025 | 15.45% |
| Sep 30, 2025 | -1.94% |
| Jun 30, 2025 | -1.34% |
| Mar 31, 2025 | 2.40% |
| Dec 31, 2024 | -35.21% |
| Sep 30, 2024 | -5.21% |
| Jun 30, 2024 | 1.03% |
| Mar 31, 2024 | -16.25% |
| Dec 31, 2023 | -25.57% |
| Sep 30, 2023 | -14.86% |
| Jun 30, 2023 | -51.24% |
| Mar 31, 2023 | -43.20% |
| Dec 31, 2022 | -53.93% |
| Sep 30, 2022 | -48.10% |